You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

June 5, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Dosage breakthrough for schizophrenia drug, plus 5 more FDA approvals

A new treatment option for a schizophrenia drug, a new therapy for a rare lung disease that strikes younger women, and more.
» Details

FDA grants priority review to expand use of Brilinta

FDA has granted priority review for ticagrelor (Brilinta, AstraZeneca) for patients with a history of heart attack. » Looking beyond current care standards

Continuing Education

MTM essentials for asthma management: Part 2

This month's CE activity is part of the CE series, MTM for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to review the stepwise approach to the management of pediatric and adult asthma and the pharmacotherapies commonly used in asthma treatment.

To read and print the article with TEST questions, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT30-PYJ23.


Announcement: The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration has been uploaded for your convenience. Current users do not need to register. To review you registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

PCORI awards prison system $2M to study naltrexone benefit in opioid abuse

The Patient-Centered Outcomes Research Institute (PCORI) awarded over $2 million to the University of Pennsylvania to conduct a prison system study assessing use of naltrexone to prevent relapse in opioid abuse. » Study details

 

RELATED ARTICLES

FDA approves first generic Abilify

FDA approves new administration option for Brilinta

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA